About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT07180524

Prospective Clinical Trial on the Impact of Uterine Firomatosis on Pelvic Floor.

Uterine fibromatosis is one of the most frequent gynecological conditions; in fact, uterine fibroids involve approximately 25-30% of women during the fertile period. Risk factors for the development o...

Lead sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Arsenio Spinillo

CONTACT

+39382503267 spinillo@smatteo.pv.it

Sponsors

Lead Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Age

35 - 55 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•Symptomatic uterine fibromatosis with intramural and/or subserosal myomas identified by ultrasound and topographically mapped
•Patients with scheduled hysterectomy or myomectomy

Exclusion Criteria

•suspicion of malignant lesion.
•active tumors
•previous history of chemotherapy or radiotherapy
•pregnancy
•age \<18 years or \>55 years (postmenopause)
•history of pelvic static disorders prior to surgery

Related studies

Natural History Study of Patients With Neurofibromatosis Type 2

NCT00598351 · Neurofibromatosis

RECRUITINGPhase 1/2

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

NCT04750928 · Neurofibromatosis 1

Familial Investigations of Childhood Cancer Predisposition

NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more

RECRUITINGPhase 2

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

NCT05735717 · Hematologic Malignancy, Acute Leukemia, and more

RECRUITINGPhase 2

A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

NCT06541847 · Neurofibromatosis Type 1

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 18, 2025Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment200

Start dateJun 2024

Last updatedSep 18, 2025

Condition

Pelvic Floor Dysfunction Fibromatosis

Locations shown

Fondazione IRCCS Policlinico San Matteo, SC Ostetricia e Ginecologia 1

Pavia, Pavia

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 18, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions